Bupropion
- Generic Name
- Bupropion
- Brand Names
- Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18ClNO
- CAS Number
- 34911-55-2
- Unique Ingredient Identifier
- 01ZG3TPX31
- Background
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...
- Indication
Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
- Associated Therapies
- Smoking, Cessation, Weight Loss
Addressing Dementia Via Agitation-Centered Evaluation
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT03226522
- Locations
- 🇦🇺
Axsome study site, Caulfield, Melbourne, Victoria, Australia
🇺🇸Axsome Study Site, Everett, Washington, United States
Buproprion for Binge Drinking
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 42
- Registration Number
- NCT03169244
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Peking University
- Target Recruit Count
- 300
- Registration Number
- NCT03148509
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Yale University
- Target Recruit Count
- 5
- Registration Number
- NCT03132571
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Duke University
- Target Recruit Count
- 45
- Registration Number
- NCT02995915
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Duke University
- Target Recruit Count
- 11
- Registration Number
- NCT02873754
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Mobile Contingency Management for Marijuana and Tobacco Cessation
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Duke University
- Target Recruit Count
- 7
- Registration Number
- NCT02869451
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
An Open Label Trial of Bupropion and Naltrexone for Binge Drinking
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 12
- Registration Number
- NCT02842073
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 312
- Registration Number
- NCT02741791
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.